Lbp Am Sa Buys 8,296 Shares of DexCom, Inc. $DXCM

Lbp Am Sa lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,453 shares of the medical device company’s stock after purchasing an additional 8,296 shares during the quarter. Lbp Am Sa’s holdings in DexCom were worth $4,809,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of DexCom by 374.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after purchasing an additional 2,294,709 shares in the last quarter. Legal & General Group Plc boosted its position in shares of DexCom by 4.7% during the 3rd quarter. Legal & General Group Plc now owns 2,635,700 shares of the medical device company’s stock worth $177,356,000 after purchasing an additional 117,493 shares in the last quarter. DSM Capital Partners LLC boosted its position in shares of DexCom by 76.5% during the 3rd quarter. DSM Capital Partners LLC now owns 2,533,539 shares of the medical device company’s stock worth $170,482,000 after purchasing an additional 1,098,243 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of DexCom during the 3rd quarter worth about $163,964,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $63.98 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The company has a market capitalization of $24.69 billion, a P/E ratio of 30.47, a P/E/G ratio of 1.19 and a beta of 1.55. The company has a fifty day moving average of $67.36 and a 200-day moving average of $66.73. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.45 earnings per share. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Mizuho raised their price target on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Robert W. Baird set a $87.00 target price on shares of DexCom in a research report on Friday, February 13th. Morgan Stanley reissued an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Citigroup lifted their price objective on shares of DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $86.50.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.